Developer docs
API playgroundTry for free, no card

Search company profiles

iTolerance

Full company profile

uuid00051i3

Namestring
iTolerance
Legal namestring
iTolerance, Inc.
Websiteurl
itolerance.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

iTolerance, Inc. is a preclinical-stage, privately-held biotechnology company developing a proprietary immunomodulatory platform (iTOL-100) built on a synthetic Streptavidin-FasL fusion protein displayed on a biotin-PEG microgel (SA-FasL microgel). The platform induces durable immune tolerance at the site of co-administered cell, tissue, or organoid therapy by triggering apoptosis of activated T-cells while expanding T-regulatory cells, eliminating the need for chronic immunosuppression that typically accompanies transplantation. The company was founded in 2020, is headquartered in Miami, Florida, and is incorporated in Delaware. It operates with 1–10 employees and is funded primarily through non-dilutive grants (notably a $1M BIRD Foundation grant in 2024) and early venture participation (e.g., Gaingels, 2022).

The company's pipeline is anchored by iTOL-101 and iTOL-102, both targeting Type 1 Diabetes via co-administration of pancreatic islets (allogeneic cadaveric for iTOL-101, stem cell-derived for iTOL-102) with iTOL-100. iTOL-102 — the lead program and the focus of the Kadimastem co-development partnership — completed a Pre-IND meeting with the FDA in February 2025. Adjacent programs extend the platform into hepatocyte/liver failure therapy (iTOL-200/iTOL-201) and large organ transplantation (iTOL-401, licensed from Georgia Tech Research Corporation). Scientific and regulatory credibility is anchored by Chief Scientist Dr. Camillo Ricordi (pioneer of clinical islet allotransplantation, H-index 119) and by co-inventors Drs. Esma Yolcu and Haval Shirwan, with peer-reviewed validation in Science Advances and Nature Materials.

The business model is licensing- and partnership-driven: iTolerance is pre-revenue, has no commercial product, and plans to monetize through co-development agreements and eventual licensing of approved therapies to larger pharmaceutical or biotech partners. The company has built a strategic and scientific advisory bench in 2025 that includes former FDA senior officials (Wayne Pines, Emily Shacter) and former Medtronic regulatory counsel (Sandra Cohen Kalter), as well as a financial advisor with a track record of raising over $1B in life sciences capital. Acknowledged collaborators include the Diabetes Research Institute (University of Miami), Breakthrough T1D (formerly JDRF), Georgia Tech, University of Louisville, University of Missouri, Kadimastem/NLS Pharmaceutics, and the BIRD Foundation.

Short descriptiontext

iTolerance is a preclinical biotech developing a proprietary SA-FasL microgel platform (iTOL-100) that enables cell, tissue, and organoid therapies without lifelong immunosuppression, with a lead Type 1 Diabetes program (iTOL-102) that completed a Pre-IND FDA meeting in 2025.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMiami, United States
HQ citystring
Miami
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicine therapies, immunomodulatory biologics, cell therapy platform, Type 1 Diabetes treatment, transplantation immunosuppression
Industry4 codes
PRIMARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Misc Health & Allied Services, Nec8090
Product category
Regenerative Medicine
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharmaceutical Product Development
TypeLicensing Royalties
Description

Pre-clinical stage biotechnology company with no current revenue. Future revenue expected from licensing agreements, co-development partnerships, and eventual commercialization of therapeutic products through FDA approval pathways.

itolerance.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

iTolerance is a preclinical regenerative medicine company developing a proprietary SA-FasL microgel platform (iTOL-100) that induces localized immune tolerance, enabling cell, tissue, and organ therapies without life-long immunosuppression. The company is advancing a pipeline of product candidates including iTOL-101 (allogeneic cadaveric islets) and iTOL-102 (stem cell-derived islets) for Type 1 Diabetes, iTOL-200/iTOL-201 for liver failure, and iTOL-401 for large organ transplantation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Demonstrated long-term graft function with control of blood glucose levels and restoration of insulin secretion without chronic immune suppression in non-human primate studies
+1 more record
Product overview1 text field

iTolerance is a preclinical regenerative medicine company developing a platform of immunomodulatory products centered on its core iTOL-100 technology, a SA-FasL microgel that enables cell, tissue, and organoid therapies without life-long immunosuppression. The company is advancing multiple pipeline programs: iTOL-101 and iTOL-102 for Type 1 Diabetes (using allogeneic cadaveric islets and stem cell-derived islets respectively), iTOL-200/iTOL-201 for liver function regeneration, and iTOL-401 for large organ transplantation. The platform's key differentiator is its ability to induce localized immune tolerance, eliminating the need for chronic immunosuppression that typically accompanies cell and organ transplants.

Product and service1 record
1iTOL-100 Immunomodulatory Platform
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-29
Description

NLS Pharmaceutics merged with Kadimastem, with whom iTolerance has an ongoing collaboration for iTOL-102. The merged company framework continues BIRD Foundation support for the ITOL-102 diabetes program. NLS is a global development-stage biopharmaceutical company focused on CNS disorders.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-25
Description

Strategic collaboration for iTOL-102 combining Kadimastem's IsletRx stem cell-derived pancreatic islets with iTolerance's iTOL-100 immunomodulator for Type 1 Diabetes treatment. Funded in part by BIRD Foundation grant. Successfully completed pre-IND meeting with FDA in February 2025. Kadimastem is a clinical-stage cell therapy company developing off-the-shelf allogeneic cell products.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration for Type 1 Diabetes cure-focused research. The DRI at University of Miami serves as fast-track center for testing iTOL-102 and designated the treatment as a potential breakthrough transplantation approach.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Breakthrough T1D (formerly Juvenile Diabetes Research Foundation) invests in research to accelerate life-changing breakthroughs to cure, prevent and treat Type 1 Diabetes. Has invested more than $2.5 billion in research funding since inception.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaborator where iTolerance technology was co-invented. Dr. Andrés García, scientific founder, is Executive Director of Parker H. Petit Institute for Bioengineering and Bioscience at Georgia Tech. iTOL-401 development is subject to license agreement with Georgia Tech Research Corporation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaborator where Dr. Haval Shirwan serves as Chair and Curators' Distinguished Professor. Dr. Esma S. Yolcu serves as Gratis Professor. Co-inventors of the SA-FasL microgel technology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaborator where Dr. Haval Shirwan serves as Curators' Distinguished Professor. Dr. Esma S. Yolcu serves as Professor. MU, Harvard and Georgia Tech collaborated on novel Type 1 Diabetes treatment development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Vertex is advancing VX-880 and VX-264, stem-cell-derived islet cell therapies for Type 1 Diabetes, making it the most directly comparable competitor to iTolerance's iTOL-102 program. Following its acquisitions of ViaCyte and Semma Therapeutics, Vertex represents the leading well-capitalized incumbent in encapsulated and stem-cell T1D therapy.

2ViaCyte (acquired by Vertex)
TypeDirect peer
Description

ViaCyte developed stem-cell-derived pancreatic islet therapies (VC-02, PEC-Direct) for Type 1 Diabetes and was acquired by Vertex in 2022. Its clinical-stage encapsulated islet platform is one of the closest technological analogues to iTolerance's iTOL-101/102 approach.

3Selecta Biosciences
TypeDirect peer
Description

Selecta developed immune tolerance platforms (ImmTOR) for biologics and gene therapies, directly addressing the same problem iTolerance's SA-FasL microgel targets: inducing antigen-specific immune tolerance to enable cell and gene therapies without chronic immunosuppression.

TypeEmerging player
Description

Anokion is a clinical-stage immune tolerance company using engineered antigen-specific approaches to treat autoimmune disease and enable cell therapies without immunosuppression. Its focus on tolerance induction overlaps directly with iTolerance's mechanism of action.

5Sigilon Therapeutics
TypeDirect peer
Description

Sigilon developed Afibromer biomaterial-encapsulated cell therapies designed to evade immune recognition without chronic immunosuppression, including programs for Type 1 Diabetes. Its encapsulated-cell approach is a direct technological competitor to iTolerance's microgel platform.

TypeDirect peer
Description

Semma developed large-scale stem-cell-derived pancreatic islet therapies for Type 1 Diabetes and was acquired by Vertex in 2019 for $950M. As the originator of the VX-880 program, it represents the most relevant prior comparable for stem-cell-derived islet economics.

TypeEmerging player
Description

Kadimastem is iTolerance's development partner for iTOL-102, supplying IsletRx stem-cell-derived pancreatic islets. As a clinical-stage cell therapy company with an overlapping diabetes focus, it is simultaneously a partner and a thematic peer in regenerative cell therapy.

TypeBroad incumbent
Description

Sana is a clinical-stage biotechnology company developing engineered cell therapies and in vivo delivery approaches, including hypoimmune cell modifications designed to evade immune rejection. Its hypoimmune platform concept is mechanistically adjacent to iTolerance's immune-tolerance approach.

TypeBroad incumbent
Description

CRISPR Therapeutics is a leading gene-editing company with programs in regenerative medicine and a partnership with ViaCyte on stem-cell-derived islets edited for immune evasion. Its edited allogeneic cell approach represents an alternative immune-evasion strategy to iTolerance's FasL microgel.

TypeBroad incumbent
Description

Evotec is a global drug discovery and cell therapy contract development organization with active programs in iPSC-derived cell therapies, including partnerships for Type 1 Diabetes. Its infrastructure and cell-therapy manufacturing capabilities make it both a potential partner and an indirect peer in the regenerative cell-therapy space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

iTolerance

Regenerative Medicineitolerance.com

iTolerance is a preclinical biotech developing a proprietary SA-FasL microgel platform (iTOL-100) that enables cell, tissue, and organoid therapies without lifelong immunosuppression, with a lead Type 1 Diabetes program (iTOL-102) that completed a Pre-IND FDA meeting in 2025.

What iTolerance does

iTolerance, Inc. is a preclinical-stage, privately-held biotechnology company developing a proprietary immunomodulatory platform (iTOL-100) built on a synthetic Streptavidin-FasL fusion protein displayed on a biotin-PEG microgel (SA-FasL microgel). The platform induces durable immune tolerance at the site of co-administered cell, tissue, or organoid therapy by triggering apoptosis of activated T-cells while expanding T-regulatory cells, eliminating the need for chronic immunosuppression that typically accompanies transplantation. The company was founded in 2020, is headquartered in Miami, Florida, and is incorporated in Delaware. It operates with 1–10 employees and is funded primarily through non-dilutive grants (notably a $1M BIRD Foundation grant in 2024) and early venture participation (e.g., Gaingels, 2022).

The company's pipeline is anchored by iTOL-101 and iTOL-102, both targeting Type 1 Diabetes via co-administration of pancreatic islets (allogeneic cadaveric for iTOL-101, stem cell-derived for iTOL-102) with iTOL-100. iTOL-102 — the lead program and the focus of the Kadimastem co-development partnership — completed a Pre-IND meeting with the FDA in February 2025. Adjacent programs extend the platform into hepatocyte/liver failure therapy (iTOL-200/iTOL-201) and large organ transplantation (iTOL-401, licensed from Georgia Tech Research Corporation). Scientific and regulatory credibility is anchored by Chief Scientist Dr. Camillo Ricordi (pioneer of clinical islet allotransplantation, H-index 119) and by co-inventors Drs. Esma Yolcu and Haval Shirwan, with peer-reviewed validation in Science Advances and Nature Materials.

The business model is licensing- and partnership-driven: iTolerance is pre-revenue, has no commercial product, and plans to monetize through co-development agreements and eventual licensing of approved therapies to larger pharmaceutical or biotech partners. The company has built a strategic and scientific advisory bench in 2025 that includes former FDA senior officials (Wayne Pines, Emily Shacter) and former Medtronic regulatory counsel (Sandra Cohen Kalter), as well as a financial advisor with a track record of raising over $1B in life sciences capital. Acknowledged collaborators include the Diabetes Research Institute (University of Miami), Breakthrough T1D (formerly JDRF), Georgia Tech, University of Louisville, University of Missouri, Kadimastem/NLS Pharmaceutics, and the BIRD Foundation.

iTolerance firmographics

Firmographics
Name
iTolerance
Legal name
iTolerance, Inc.
Website
https://itolerance.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
iTolerance is a preclinical biotech developing a proprietary SA-FasL microgel platform (iTOL-100) that enables cell, tissue, and organoid therapies without lifelong immunosuppression, with a lead Type 1 Diabetes program (iTOL-102) that completed a Pre-IND FDA meeting in 2025.
Ownership category
akta.pro rank

iTolerance industry classification

Industry
Product category
Regenerative Medicine
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Regenerative medicine therapies
  • Immunomodulatory biologics
  • Cell therapy platform
  • Type 1 Diabetes treatment
  • Transplantation immunosuppression

Where iTolerance is headquartered

Location

Headquarters

HQ city
Miami
HQ country
United States
HQ region
North America

Offices1 record

Markets served

iTolerance business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Biopharmaceutical Product Development: Pre-clinical stage biotechnology company with no current revenue. Future revenue expected from licensing agreements, co-development partnerships, and eventual commercialization of therapeutic products through FDA approval pathways.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

iTolerance product offering

Product offering

Core offering

iTolerance is a preclinical regenerative medicine company developing a proprietary SA-FasL microgel platform (iTOL-100) that induces localized immune tolerance, enabling cell, tissue, and organ therapies without life-long immunosuppression. The company is advancing a pipeline of product candidates including iTOL-101 (allogeneic cadaveric islets) and iTOL-102 (stem cell-derived islets) for Type 1 Diabetes, iTOL-200/iTOL-201 for liver failure, and iTOL-401 for large organ transplantation.

Product overview

iTolerance is a preclinical regenerative medicine company developing a platform of immunomodulatory products centered on its core iTOL-100 technology, a SA-FasL microgel that enables cell, tissue, and organoid therapies without life-long immunosuppression. The company is advancing multiple pipeline programs: iTOL-101 and iTOL-102 for Type 1 Diabetes (using allogeneic cadaveric islets and stem cell-derived islets respectively), iTOL-200/iTOL-201 for liver function regeneration, and iTOL-401 for large organ transplantation. The platform's key differentiator is its ability to induce localized immune tolerance, eliminating the need for chronic immunosuppression that typically accompanies cell and organ transplants.

Differentiator

Problem solved

Functional benefit

Products and services

  • iTOL-100 Immunomodulatory Platform

Quantifiable outcome

  • Demonstrated long-term graft function with control of blood glucose levels and restoration of insulin secretion without chronic immune suppression in non-human primate studies
  • +1 more outcomes

Companies that use iTolerance

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

iTolerance technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

iTolerance partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • NLS PharmaceuticscoreStrategic or Co-development Partner · 29 October 2025NLS Pharmaceutics merged with Kadimastem, with whom iTolerance has an ongoing collaboration for iTOL-102. The merged company framework continues BIRD Foundation support for the ITOL-102 diabetes program. NLS is a global development-stage biopharmaceutical company focused on CNS disorders.
  • KadimastemcoreStrategic or Co-development Partner · 25 February 2025Strategic collaboration for iTOL-102 combining Kadimastem's IsletRx stem cell-derived pancreatic islets with iTolerance's iTOL-100 immunomodulator for Type 1 Diabetes treatment. Funded in part by BIRD Foundation grant. Successfully completed pre-IND meeting with FDA in February 2025. Kadimastem is a clinical-stage cell therapy company developing off-the-shelf allogeneic cell products.
  • Diabetes Research Institute FoundationcoreStrategic or Co-development PartnerCollaboration for Type 1 Diabetes cure-focused research. The DRI at University of Miami serves as fast-track center for testing iTOL-102 and designated the treatment as a potential breakthrough transplantation approach.
  • Breakthrough T1D (formerly JDRF)minorStrategic or Co-development PartnerBreakthrough T1D (formerly Juvenile Diabetes Research Foundation) invests in research to accelerate life-changing breakthroughs to cure, prevent and treat Type 1 Diabetes. Has invested more than $2.5 billion in research funding since inception.
  • Georgia Institute of TechnologycoreStrategic or Co-development PartnerAcademic collaborator where iTolerance technology was co-invented. Dr. Andrés García, scientific founder, is Executive Director of Parker H. Petit Institute for Bioengineering and Bioscience at Georgia Tech. iTOL-401 development is subject to license agreement with Georgia Tech Research Corporation.
  • University of LouisvillecoreStrategic or Co-development PartnerAcademic collaborator where Dr. Haval Shirwan serves as Chair and Curators' Distinguished Professor. Dr. Esma S. Yolcu serves as Gratis Professor. Co-inventors of the SA-FasL microgel technology.
  • University of MissouricoreStrategic or Co-development PartnerAcademic collaborator where Dr. Haval Shirwan serves as Curators' Distinguished Professor. Dr. Esma S. Yolcu serves as Professor. MU, Harvard and Georgia Tech collaborated on novel Type 1 Diabetes treatment development.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

iTolerance competitors and assessment

Company assessment

Direct peers

  • Vertex Pharmaceuticals: Vertex is advancing VX-880 and VX-264, stem-cell-derived islet cell therapies for Type 1 Diabetes, making it the most directly comparable competitor to iTolerance's iTOL-102 program. Following its acquisitions of ViaCyte and Semma Therapeutics, Vertex represents the leading well-capitalized incumbent in encapsulated and stem-cell T1D therapy.
  • ViaCyte (acquired by Vertex): ViaCyte developed stem-cell-derived pancreatic islet therapies (VC-02, PEC-Direct) for Type 1 Diabetes and was acquired by Vertex in 2022. Its clinical-stage encapsulated islet platform is one of the closest technological analogues to iTolerance's iTOL-101/102 approach.
  • Selecta Biosciences: Selecta developed immune tolerance platforms (ImmTOR) for biologics and gene therapies, directly addressing the same problem iTolerance's SA-FasL microgel targets: inducing antigen-specific immune tolerance to enable cell and gene therapies without chronic immunosuppression.
  • Sigilon Therapeutics: Sigilon developed Afibromer biomaterial-encapsulated cell therapies designed to evade immune recognition without chronic immunosuppression, including programs for Type 1 Diabetes. Its encapsulated-cell approach is a direct technological competitor to iTolerance's microgel platform.
  • Semma Therapeutics (acquired by Vertex): Semma developed large-scale stem-cell-derived pancreatic islet therapies for Type 1 Diabetes and was acquired by Vertex in 2019 for $950M. As the originator of the VX-880 program, it represents the most relevant prior comparable for stem-cell-derived islet economics.

Emerging players

  • Anokion: Anokion is a clinical-stage immune tolerance company using engineered antigen-specific approaches to treat autoimmune disease and enable cell therapies without immunosuppression. Its focus on tolerance induction overlaps directly with iTolerance's mechanism of action.
  • Kadimastem (merged into NLS Pharmaceutics): Kadimastem is iTolerance's development partner for iTOL-102, supplying IsletRx stem-cell-derived pancreatic islets. As a clinical-stage cell therapy company with an overlapping diabetes focus, it is simultaneously a partner and a thematic peer in regenerative cell therapy.

Broad incumbents

  • Sana Biotechnology: Sana is a clinical-stage biotechnology company developing engineered cell therapies and in vivo delivery approaches, including hypoimmune cell modifications designed to evade immune rejection. Its hypoimmune platform concept is mechanistically adjacent to iTolerance's immune-tolerance approach.
  • CRISPR Therapeutics: CRISPR Therapeutics is a leading gene-editing company with programs in regenerative medicine and a partnership with ViaCyte on stem-cell-derived islets edited for immune evasion. Its edited allogeneic cell approach represents an alternative immune-evasion strategy to iTolerance's FasL microgel.
  • Evotec SE: Evotec is a global drug discovery and cell therapy contract development organization with active programs in iPSC-derived cell therapies, including partnerships for Type 1 Diabetes. Its infrastructure and cell-therapy manufacturing capabilities make it both a potential partner and an indirect peer in the regenerative cell-therapy space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

iTolerance social profiles

Digital presence

iTolerance financial estimates

Financial estimate

Revenue estimate

Valuation estimate

iTolerance leadership team

Management profile

Number of profiles

Profiles11 records

iTolerance funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

iTolerance M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iTolerance

What does iTolerance do?

iTolerance is a preclinical regenerative medicine company developing a proprietary SA-FasL microgel platform (iTOL-100) that induces localized immune tolerance, enabling cell, tissue, and organ therapies without life-long immunosuppression. The company is advancing a pipeline of product candidates including iTOL-101 (allogeneic cadaveric islets) and iTOL-102 (stem cell-derived islets) for Type 1 Diabetes, iTOL-200/iTOL-201 for liver failure, and iTOL-401 for large organ transplantation.

Is iTolerance a public or private company?

iTolerance is a private company. It is classified as unknown and is currently operating.

When was iTolerance founded?

iTolerance was founded in 2020. It employs 1 to 10 people.

Where is iTolerance based?

iTolerance is headquartered in Miami, United States, in the North America region.

How does iTolerance make money?

One revenue line is on record: biopharmaceutical Product Development.

Who are iTolerance's main competitors?

Direct peers on record are Vertex Pharmaceuticals, ViaCyte (acquired by Vertex), Selecta Biosciences, Sigilon Therapeutics and Semma Therapeutics (acquired by Vertex). Emerging players are Anokion and Kadimastem (merged into NLS Pharmaceutics). Broad incumbents are Sana Biotechnology, CRISPR Therapeutics and Evotec SE.

Does iTolerance have an API?

No public API is recorded for iTolerance.

What industry is iTolerance in?

iTolerance's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAAAGAL, Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 541714 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireBioFlorida Announces Appointment of Dr. Anthony Japour, CEO of iTolerance, Inc., as Chair of the Southeast ChapterBioFlorida appointed Dr. Anthony Japour, CEO of iTolerance, Inc., as the Chair of its Southeast Chapter, effective December 15, 2025. In this role, Dr. Japour will collaborate with BioFlorida leadership to advance the life sciences ecosystem and foster collaboration within Southeast Florida.PR NewswireDelveInsight Evaluates a Robust Diabetes Pipeline as 200+ Influential Pharma Players to Set Foot in the DomainDelveInsight's Diabetes Pipeline Insight 2023 report identifies over 200 active pharmaceutical players developing more than 200 pipeline therapies for diabetes treatment, highlighting a robust and competitive landscape. Notable recent developments include Sanofi's $35 million equity investment in Provention Bio, Provention Bio's FDA approval of Tzield for type 1 diabetes, Biocon's semi-exclusive partnership with Zentiva for Liraglutide commercialization across 30 European countries, and iTolerance's collaboration with the Diabetes Research Institute for its iTOL-100 platform technology.MIT Technology ReviewThis company is about to grow new organs in a person for the first timeLyGenesis is set to begin clinical trials in Boston, Massachusetts, involving the injection of donor liver cells into lymph nodes to grow miniature secondary livers for patients with severe liver disease. The company aims to utilize discarded donor organs to treat up to 75 individuals per organ and has partnered with iTolerance to potentially eliminate the need for lifelong immunosuppressant drugs.PR NewswireiTolerance and LyGenesis Announce a Joint Research Collaboration to Regrow Functioning, Ectopic Livers Without the Need for Immune SuppressioniTolerance, Inc. and LyGenesis, Inc. announced a joint research collaboration to evaluate the combined potential of iTolerance's SA FasL microgel immune tolerance platform (iTOL-100) with LyGenesis's liver cell therapy (LYG-LIV-100) for growing ectopic functioning livers without the need for immune suppression. The collaboration has generated in vitro data and is progressing toward small animal proof-of-concept work to evaluate whether the combined technology can rescue animals from otherwise fatal liver disease without immunosuppression. LyGenesis noted it has turned attention toward a second-generation therapy for organ regeneration, while iTolerance sees synergies that could drive value for both biotech companies and ultimately benefit patients.